DrugPatentWatch Database Preview

Details for Patent: 6,432,452

« Back to Dashboard

Which drugs does patent 6,432,452 protect, and when does it expire?

Patent 6,432,452 protects PICATO and is included in one NDA.

This patent has eighteen patent family members in fifteen countries.

Summary for Patent: 6,432,452

Title:	Anti-cancer compounds
Abstract:	This invention relates to a compound or group of compounds present in an active principle derived from plants of the species Euphorbia peplus, Euphorbia hirta and Euphorbia drummondii, and to pharmaceutical compositions comprising these compounds. Extracts from these plants have been found to show selective cytotoxicity against several different cancer cell lines. The compounds are useful in effective treatment of cancers, particularly malignant melanomas and squamous cell carcinomas (SCCs). In a preferred embodiment of the invention, the compound is selected from the group consisting of jatrophanes, pepluanes, paralianes and ingenanes, and pharmaceutically-acceptable salts or esters thereof, and more particularly jatrophanes of Conformation II.
Inventor(s):	Aylward; James Harrison (St. Lucia, AU)
Assignee:	Peplin Biotech Pty. Ltd. (Fortitude Valley, AU)
Application Number:	09/486,199
Patent Claim Types: see list of patent claims	Use; Process;

Drugs Protected by US Patent 6,432,452

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Patented / Exclusive Use	Patent Submitted
Leo Labs	PICATO	ingenol mebutate	GEL;TOPICAL	202833-001	Jan 23, 2012		RX	Yes	Yes						TREATMENT OF ACTINIC KERATOSIS
Leo Labs	PICATO	ingenol mebutate	GEL;TOPICAL	202833-002	Jan 23, 2012		RX	Yes	Yes						TREATMENT OF ACTINIC KERATOSIS

Foreign Priority and PCT Information for Patent: 6,432,452

Foriegn Application Priority Data
Foreign Country	Foreign Patent Number	Foreign Patent Date
Australia	PO 8640	Aug 19, 1997

PCT Information
PCT Filed	August 19, 1998	PCT Application Number:	PCT/AU98/00656
PCT Publication Date:	February 25, 1999	PCT Publication Number:	WO99/08994

Non-Orange Book US Patents Family Members for Patent 6,432,452

For Orange Book-listed patents (shown in the main table above) generic applications must certify that the listed patents are expired, invalid, or will not be infringed by generic entry.

The non-Orange Book patents listed below do not require formal certifications, so they do not automatically impede generic entry. Instead, they represent potential opportunities for branded firms to block generic entry through patent infringment challenges.

Patent No.	Title	Estimated Patent Expiration
7,410,656	Anti-cancer compounds
6,787,161	Anti-cancer compounds
6,844,013	Methods of stimulating the immune system

International Patents Family Members for US Patent 6,432,452

Country	Document Number	Estimated Expiration	Supplementary Protection Certificate	SPC Country	SPC Expiration
Brazil	9811327
Canada	2301082
China	1266421
Cyprus	1108303